Product image of Janecluc (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Janecluc

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Janecluc (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Janecluc, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH India supplies Janecluc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Demo Abee

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Janecluc is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

  • Type 2 diabetes mellitus (initial therapy): provides improved glycaemic control as first‑line treatment.
  • Type 2 diabetes mellitus (add‑on therapy): enhances glucose lowering when metformin alone is insufficient.
  • Type 2 diabetes mellitus (dual therapy): offers combined biguanide and DPP‑4 inhibition for patients requiring multiple mechanisms of action.

How It Works

  • Metformin reduces hepatic glucose production and increases peripheral insulin sensitivity by activating AMP‑activated protein kinase. Sitagliptin inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, prolonging the activity of incretin hormones (GLP‑1 and GIP), which enhances glucose‑dependent insulin secretion and suppresses glucagon release, together achieving better glycaemic control.

Side Effects

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or flatulence.
  • Diarrhoea: loose stools occurring especially after dose initiation.
  • Headache: mild to moderate intensity.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Fatigue: feeling of tiredness without exertion.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic disturbance.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Pancreatitis: acute inflammation of the pancreas.
  • Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatic dysfunction: marked elevation of liver enzymes.

Precautions & Warnings

Before initiating Janecluc, clinicians should assess patient suitability and monitor for adverse outcomes.

  • Renal function: evaluate eGFR and avoid use in severe renal impairment.
  • Hepatic status: check liver enzymes; use cautiously in hepatic disease.
  • Risk of lactic acidosis: avoid in conditions predisposing to hypoxia.
  • Elderly patients: start at lower dose and monitor tolerance.
  • Concomitant medications: review for drugs that may affect glucose levels.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Janecluc may interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Iodinated contrast agents: can precipitate renal failure, increasing metformin accumulation.
  • Cimetidine: raises sitagliptin plasma concentrations, heightening risk of side effects.
  • Rifampin: markedly reduces sitagliptin exposure, diminishing efficacy.

Moderate Interactions (Monitor Closely)

  • Diuretics: may affect renal clearance of metformin.
  • ACE inhibitors or ARBs: combined effect on renal function warrants monitoring.
  • NSAIDs: can impair renal function, increasing metformin levels.
  • Alcohol: potentiates risk of lactic acidosis.
  • Beta‑blockers: may mask hypoglycaemia symptoms.

Frequently Asked Questions

Janecluc is a prescription oral medication that combines metformin and sitagliptin to improve blood glucose control in adults with type 2 diabetes mellitus, either as initial therapy or when additional glucose‑lowering effect is needed.

Metformin decreases hepatic glucose output and enhances insulin sensitivity, while sitagliptin blocks the DPP‑4 enzyme, prolonging incretin activity that stimulates insulin release and reduces glucagon secretion, together lowering blood sugar levels.

The dose of Janecluc is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Janecluc in pregnancy or lactation has not been definitively established. Healthcare providers should weigh potential benefits against risks and consider alternative treatments if appropriate for pregnant or nursing women.

To request Janecluc, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Janecluc offers the combined mechanisms of a biguanide and a DPP‑4 inhibitor in a single tablet, which can simplify regimens compared with taking separate agents. It may provide better glycaemic control than metformin alone and avoids the injectable route required for some GLP‑1 analogues.

Janecluc should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain product stability.

Janecluc is taken orally, usually once daily with or after a meal. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis from metformin, severe hypoglycaemia when combined with insulin or sulfonylureas, pancreatitis, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience symptoms suggestive of these conditions.

Janecluc is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and in those with a history of lactic acidosis. Caution is also advised for individuals with hepatic disease or significant cardiac failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT